PALATIN TECHNOLOGIES INC

Palatin Technologies Inc.

Biotechnology • Healthcare • Monmouth Junction, NJ, United States • PTNT (PNK)

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

609 495 2200 11 Deer Park Drive, Monmouth Junction, NJ 08512, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Layoff Events
Earnings Calls
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Earnings Call Transcripts

View All →
Q4 2025 Positive
Nov 6, 2025

Palatin Technologies, Inc. (PTNT) announced a public offering expected to raise $15.8 million, alongside a successful reverse stock split, enabling its planned relisting on the NYSE American exchange by November 12, 2025. This capital raise, combined with $8.8 million in collaboration revenue for the quarter ended September 30, 2025, ensures compliance with NYSE American listing standards.

Recent News

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option - PR Newswire
PR Newswire • Nov 12
Here's Why Palatin Technologies (PTN) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Yahoo Finance • Mar 13
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering - PR Newswire
PR Newswire • Nov 6
Palatin Technologies faces delisting over equity shortfall - The Pharma Letter
The Pharma Letter • Apr 11
Palatin Technologies resumes NYSE trading after $18.2 million offering - Investing.com
Investing.com • Nov 12

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has PALATIN TECHNOLOGIES INC had layoffs?
No layoff events have been recorded for PALATIN TECHNOLOGIES INC in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does PALATIN TECHNOLOGIES INC have?
PALATIN TECHNOLOGIES INC has approximately 29 employees.
What industry is PALATIN TECHNOLOGIES INC in?
PALATIN TECHNOLOGIES INC operates in the Biotechnology industry, within the Healthcare sector.
Is PALATIN TECHNOLOGIES INC a publicly traded company?
Yes, PALATIN TECHNOLOGIES INC is publicly traded under the ticker symbol PTNT on the PNK. The company has a market capitalization of approximately $0.04 billion.
Where is PALATIN TECHNOLOGIES INC headquartered?
PALATIN TECHNOLOGIES INC is headquartered in Monmouth Junction, NJ, United States at 11 Deer Park Drive, Monmouth Junction, NJ 08512, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.